ESTRO 2022 - Abstract Book

S1158

Abstract book

ESTRO 2022

Conclusion Early results from PSICHE trial showed that macroscopic disease is detected in a significant percentage of patients affected by early BR. PSMA staging is necessary in this setting to avoid undertreatment and allow tailored treatment.

PO-1364 Early toxicity and PROMS in patients receiving ultrahypofractionated PBT for prostate cancer

L. Evans 1 , J. Lester 2

1 Rutherford Cancer Centres, Rutherford Innovations, Newport, United Kingdom; 2 Rutherford Cancer Centres, Rutherford Cancer Care, Newport, United Kingdom Purpose or Objective To present prospectively collected acute toxicity data and patient reported outcome measures (PROMs) in patients treated for prostate cancer (PCa) with ultrahypofractionated proton beam therapy (PBT). Materials and Methods 48 men with histologically proven prostate cancer received PBT between January 2019 and January 2021 at our centre. Of these, 9 men were excluded as they did not return follow-up PROMS questionnaires; 39 patients were included in this analysis. Clinical toxicity data was captured and analysed using both Radiotherapy Toxicity Oncology Group (RTOG) and the Expanded Prostate Cancer Index Composite (EPIC) grading and questionnaires. Results In the acute period (< 90 days from treatment completion), no patients exhibited >grade 2 genitourinary and/or gastrointestinal toxicities. RTOG data show the commonest acute genitourinary toxicities were urinary frequency (25/39 patients, 64%) and dysuria (8/39 patients, 21%) and the most common acute gastrointestinal toxicities were diarrhoea (4/39 patients, 10%) and flatulence (3/39 patients, 8%). The EPIC questionnaire PROMs were consistent the oncologist RTOG toxicity gradings. Conclusion Both RTOG and PROMs data show that ultrahypofractionated proton beam therapy for PCa results in acceptable levels of acute genitourinary and gastrointestinal toxicities.

PO-1365 SBRT for locally recurrent prostate cancer after prostatectomy and post-operative radiotherapy

W. Majewski 1 , B. Goc 1 , D. Graupner 1 , M. Miszczyk 1

1 Maria Sklodowska-Curie National Research Institute of Oncology, Radiotherapy Department, Gliwice, Poland

Purpose or Objective Patients with local recurrence after prostatectomy and post-operative radiotherapy are a real challenge for salvage treatment. The local treatment options are limited and literature on that issue is scarce. This study aims to evaluate the value of stereotactic body radiation therapy (SBRT) in the treatment of local recurrence, in patients who had already undergone salvage or adjuvant post-prostatectomy radiotherapy to the prostate bed.